Matt Lastrapes
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Matt Lastrapes has a total of 84 co-authors. Here are the top co-authors by number of shared publications:
- Aarushi Jain
Department of Medicine, Harvard Medical School and Massachusetts General Hospital, Boston, Massachusetts
15 shared publications - Albert Eusik Kim
Department of Neurology, Massachusetts General Hospital and Harvard Medical School , 55 Fruit Street, Boston, MA 02114
15 shared publications - Alexander Kaplan
Department of Medicine, Harvard Medical School and Massachusetts General Hospital, Boston, Massachusetts
15 shared publications - Andrew W. Navia
Broad Institute of MIT and Harvard
15 shared publications - Arlene H. Sharpe
Broad Institute of MIT and Harvard, Cambridge, MA, USA
15 shared publications - Ashish Dahal
Harvard Med Sch, Boston, MA 02115 USA
15 shared publications
Latest Publications
- Open Access
- 5 September 2025
- Published by Springer Nature in Nature
- Vol. 645 (8082) , 1
Author Correction: PPP2R1A mutations portend improved survival after cancer immunotherapy
- 5 September 2025
- Published by Springer Nature in Nature
- Vol. 645 (8082) , 1
Open AccessAuthor Correction: PPP2R1A mutations portend improved survival after cancer immunotherapy
- Open Access
- 2 July 2025
- Published by Springer Nature in Nature
- Vol. 644 (8076) , 537-546
PPP2R1A mutations portend improved survival after cancer immunotherapy
Immune checkpoint blockade (ICB) therapy is effective against many cancers, although resistance remains a major issue and new strategies are needed to improve clinical outcomes1,2,3,4,5. Here we studied ICB response in a cohort of patients with ovarian clear cell carcinoma—a cancer type that poses considerable clinical challenges and lacks effective therapies6,7,8. We observed significantly prolonged overall survival and progression-free survival in patients with tumours with PPP2R1A mutations. Importantly, our findings were validated in additional ICB-treated patient cohorts across multiple cancer types. Translational analyses from tumour biopsies demonstrated enhanced IFNγ signalling, and the presence of tertiary lymphoid structures at the baseline, as well as enhanced immune infiltration and expansion of CD45RO+CD8+ T cells in the tumour neighbourhood after ICB treatment in PPP2R1A-mutated tumours. Parallel preclinical investigations showed that targeting PPP2R1A (by pharmacological inhibition or genetic modifications) in in vitro and in vivo models was associated with improved survival in the setting of treatment with several forms of immunotherapy, including chimeric antigen receptor (CAR)-T cell therapy and ICB. The results from these studies suggest that therapeutic targeting of PPP2R1A may represent an effective strategy to improve patient outcomes after ICB or other forms of immunotherapy, although additional mechanistic and therapeutic insights are needed.
- 2 July 2025
- Published by Springer Nature in Nature
- Vol. 644 (8076) , 537-546
Open AccessPPP2R1A mutations portend improved survival after cancer immunotherapy
Immune checkpoint blockade (ICB) therapy is effective against many cancers, although resistance remains a major issue and new strategies are needed to improve clinical outcomes1,2,3,4,5. Here we studied ICB response in a cohort of patients with ovarian clear cell carcinoma—a cancer type that poses considerable clinical challenges and lacks effective therapies6,7,8. We observed significantly prolonged overall survival and progression-free survival in patients with tumours with PPP2R1A mutations. Importantly, our findings were validated in additional ICB-treated patient cohorts across multiple cancer types. Translational analyses from tumour biopsies demonstrated enhanced IFNγ signalling, and the presence of tertiary lymphoid structures at the baseline, as well as enhanced immune infiltration and expansion of CD45RO+CD8+ T cells in the tumour neighbourhood after ICB treatment in PPP2R1A-mutated tumours. Parallel preclinical investigations showed that targeting PPP2R1A (by pharmacological inhibition or genetic modifications) in in vitro and in vivo models was associated with improved survival in the setting of treatment with several forms of immunotherapy, including chimeric antigen receptor (CAR)-T cell therapy and ICB. The results from these studies suggest that therapeutic targeting of PPP2R1A may represent an effective strategy to improve patient outcomes after ICB or other forms of immunotherapy, although additional mechanistic and therapeutic insights are needed.
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Microenvironmental Landscape of Human Melanoma Brain Metastases in Response to Immune Checkpoint Inhibition
Supplementary Data from Microenvironmental Landscape of Human Melanoma Brain Metastases in Response to Immune Checkpoint Inhibition
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Microenvironmental Landscape of Human Melanoma Brain Metastases in Response to Immune Checkpoint Inhibition
Supplementary Data from Microenvironmental Landscape of Human Melanoma Brain Metastases in Response to Immune Checkpoint Inhibition
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Microenvironmental Landscape of Human Melanoma Brain Metastases in Response to Immune Checkpoint Inhibition
Supplementary Data from Microenvironmental Landscape of Human Melanoma Brain Metastases in Response to Immune Checkpoint Inhibition
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Microenvironmental Landscape of Human Melanoma Brain Metastases in Response to Immune Checkpoint Inhibition
Supplementary Data from Microenvironmental Landscape of Human Melanoma Brain Metastases in Response to Immune Checkpoint Inhibition
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Microenvironmental Landscape of Human Melanoma Brain Metastases in Response to Immune Checkpoint Inhibition
Supplementary Data from Microenvironmental Landscape of Human Melanoma Brain Metastases in Response to Immune Checkpoint Inhibition
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Microenvironmental Landscape of Human Melanoma Brain Metastases in Response to Immune Checkpoint Inhibition
Supplementary Data from Microenvironmental Landscape of Human Melanoma Brain Metastases in Response to Immune Checkpoint Inhibition
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Microenvironmental Landscape of Human Melanoma Brain Metastases in Response to Immune Checkpoint Inhibition
Supplementary Data from Microenvironmental Landscape of Human Melanoma Brain Metastases in Response to Immune Checkpoint Inhibition
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Microenvironmental Landscape of Human Melanoma Brain Metastases in Response to Immune Checkpoint Inhibition
Supplementary Data from Microenvironmental Landscape of Human Melanoma Brain Metastases in Response to Immune Checkpoint Inhibition
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Microenvironmental Landscape of Human Melanoma Brain Metastases in Response to Immune Checkpoint Inhibition
Supplementary Data from Microenvironmental Landscape of Human Melanoma Brain Metastases in Response to Immune Checkpoint Inhibition
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Microenvironmental Landscape of Human Melanoma Brain Metastases in Response to Immune Checkpoint Inhibition
Supplementary Data from Microenvironmental Landscape of Human Melanoma Brain Metastases in Response to Immune Checkpoint Inhibition
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Microenvironmental Landscape of Human Melanoma Brain Metastases in Response to Immune Checkpoint Inhibition
Supplementary Data from Microenvironmental Landscape of Human Melanoma Brain Metastases in Response to Immune Checkpoint Inhibition
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Microenvironmental Landscape of Human Melanoma Brain Metastases in Response to Immune Checkpoint Inhibition
Supplementary Data from Microenvironmental Landscape of Human Melanoma Brain Metastases in Response to Immune Checkpoint Inhibition
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure from Microenvironmental Landscape of Human Melanoma Brain Metastases in Response to Immune Checkpoint Inhibition
Supplementary Figure from Microenvironmental Landscape of Human Melanoma Brain Metastases in Response to Immune Checkpoint Inhibition
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure from Microenvironmental Landscape of Human Melanoma Brain Metastases in Response to Immune Checkpoint Inhibition
Supplementary Figure from Microenvironmental Landscape of Human Melanoma Brain Metastases in Response to Immune Checkpoint Inhibition
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Microenvironmental Landscape of Human Melanoma Brain Metastases in Response to Immune Checkpoint Inhibition
Supplementary Data from Microenvironmental Landscape of Human Melanoma Brain Metastases in Response to Immune Checkpoint Inhibition
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Microenvironmental Landscape of Human Melanoma Brain Metastases in Response to Immune Checkpoint Inhibition
Supplementary Data from Microenvironmental Landscape of Human Melanoma Brain Metastases in Response to Immune Checkpoint Inhibition